This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Code Systems

Code Systems

This page describes the CodeSystems of the Molecular Tumor Board module (naming convention MII_CS_<Module>_<Name>). The ValueSets built on them are described on the Value Sets page.

Important: CodeSystem resources of external terminologies (e.g. ICD-10-GM, OPS, SNOMED CT) are not published in this module; they are obtained from the central KDS terminology service (SU-TermServ): https://mii-termserv.de/.

The complete list of defined CodeSystems, ValueSets and ConceptMaps is generated automatically by the IG Publisher on the artifacts summary. Below are the domain notes on the module's own terminologies (description of own value sets, use of international terminologies, sources).

Defined CodeSystems

Treatment episode: diagnosis: guideline-treatment status

Used in the treatment episode. Source: DNPM v2.0

Treatment episode: prior therapy: approval status (Zulassungsstatus)

Used in the guideline documentation. Source: DNPM v2.0

Treatment episode: specimen: method for determining tumor-cell content

Used in the tumor-cell content. Source: DNPM v2.0

Treatment episode: therapy plan: human-genetic counselling: reason for the request

Used in the human-genetic counselling. Source: DNPM v2.0

Treatment episode: therapy recommendation: level of evidence

Used in the therapy-recommendation evidence grading. Source: 10.1002/ijc.32358

Treatment episode: therapy recommendation: level-of-evidence addendum reference

Used in the evidence grading of a therapy recommendation. Source: 10.1002/ijc.32358

Treatment episode: therapy recommendation: reason for the status (absence of a therapy recommendation)

Used in the therapy plan. Source: DNPM v2.0

Follow-up: status

Used in the follow-up ClinicalImpression.

Follow-up: dose density

Used in follow-up systemic therapy (MedicationStatement). Source: DNPM v2.0

Follow-up: response finding assessment

Used in the response finding. Source: DNPM v2.0

Follow-up: response finding assessment method

Used in the response finding. Source: DNPM v2.0

Follow-up: systemic-therapy status reason

Used for the systemic therapy (both prior therapy and follow-up). Source: DNPM v2.0

Follow-up: cost-coverage application stage (Antragsstadium)

Used in the cost-coverage application.

Follow-up: cost-coverage response decision

Used in the cost-coverage response.

Follow-up: cost-coverage response rejection reason

Used in the cost-coverage response.

NGS report: device type

Used in the genomic study analysis.

NGS report: methodology

Used in the genomic study analysis. Source: DNPM v2.0

NGS report: MSI determination: methodology

Used for the microsatellite instability. Source: DNPM v2.0

NGS report: molecular biomarkers

Used in the molecular biomarker profile.

Defined ValueSets

Diagnosis: tumor spread

Used for the tumor spread. Source: DNPM v2.0

Diagnosis: WHO grade for CNS tumors

Used for the WHO grade (CNS). Contains all child concepts of the SNOMED CT code

396921005 World Health Organization grade finding for central nervous system tumor (finding)

see https://browser.ihtsdotools.org/?perspective=full&conceptId1=396921005&edition=MAIN/2025-07-01&release=&languages=en

NGS report: methodology

Used in the genomic study analysis. Contains all codes of the "NGS report: methodology" CodeSystem defined here plus all codes of http://hl7.org/fhir/uv/genomics-reporting/CodeSystem/genomic-study-method-type-cs.

NGS report: microsatellite instability

Used for the microsatellite instability.

Follow-up: systemic-therapy status

Restricted version of the systemic-therapy status CodeSystem. Used for the systemic therapy.

Follow-up: cost-coverage type

Used for the cost-coverage application and response.

Follow-up: reason for non-implementation

Used for the follow-up ClinicalImpression.

Molecular pathology report: MMR expression

Used for the immunohistochemistry MMR/MSI.

Molecular pathology report: MMR proficiency

Used for the immunohistochemistry MMR/MSI.

Systemic prior therapy: therapy-status reason per oBDS

Source: DNPM v2.1 incl. MVGenomSeq

Systemic prior therapy: therapy-status reason per SNOMED CT

Source: DNPM v2.1 incl. MVGenomSeq